



*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

## Revision of PRECAUTIONS

### Telmisartan/Hydrochlorothiazide

June 3, 2014

#### Non-proprietary Name

Telmisartan/Hydrochlorothiazide

#### Safety measure

Precautions section should be revised in the package inserts.

In Precautions for concomitant use subsection of Interactions section, information on angiotensin-converting enzyme inhibitors (ACEIs) should be revised to include the following texts (underlined parts are revised):

#### ACEIs

Clinical symptoms and measures:

Renal impairment (including acute renal failure), hyperkalaemia, and/or hypotension may occur. Patients should be carefully monitored for renal function, serum potassium level, and blood pressure.

Mechanism and risk factors:

Concomitant use with ACEIs may increase an effect of renin-angiotensin system blockade.

In *Other drugs that have an antihypertensive effect* paragraph of Precautions for concomitant use subsection, 'ACEI' should be deleted.